Bibliometrics analysis of Vedolizumab based on Web of Science
Objective To analyze the current research status and hotspots of vedolizumab based on bibliometric analysis.Methods Relevant research literature on Vedolizumab published in the Web of Science(WOS)core database from 2013 to 2022 was retrieved.CiteSpace software was used to statistically analyze key characteristics such as publication volume,countries/regions,institutions,authors,and journals.Results A total of 1 091 papers were included,showing an over-all increasing trend in publication volume over the years.Research was conducted in 74 countries/regions,with the Unit-ed States having the highest number of publications(386 papers).A total of 329 institutions were involved in this field,with the University of California,San Diego leading in publication volume(74 papers),while Tel Aviv University and Takeda Pharmaceutical Company had the highest centrality(0.13 each).The author with the most publications was Pro-fessor Peyrin-Biroulet L from the University of Lorraine,France(52 papers),while the most cited author was Professor Sandborn WJ from the University of California,San Diego(670 citations).A total of 236 journals published related liter-ature,with Inflammatory Bowel Diseases having the most publications(94 papers),and Alimentary Pharmacology &the Rapeutics being the most cited journal(1 155 citations).Research hotspots in this field primarily focus on the clinical evaluation of the safety and efficacy of Vedolizumab,therapeutic drug monitoring,dose adjustment,and target selection.Conclusions With the widespread application of Vedolizumab in the treatment of inflammatory bowel disease(IBD),the scope of research is continuously expanding.In the future,China should pay more attention to the research hotspots in this field and strengthen international exchanges and cooperation to effectively address the rapid development of IBD with-in the country.
NETL
NSTL
万方数据
